GlassScriptPhysician profile
Robert A Sikora
NPI 1447254263
$5,036.42
in general payments reported to CMS, 2019-2025
26 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $128 · 2021: $489 · 2022: $860 · 2023: $808 · 2024: $807 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Education: $31.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.17 |
| Education | $31.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,541.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,057.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $735.72 | 2019-2025 | Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $601.87 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $201.14 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2021 | |
| Amgen INC. | $92.06 | 2021-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $90.57 | 2022-2025 | Hyqvia, Cuvitru |
| Pfizer INC. | $82.89 | 2022-2024 | |
| Shire North American Group INC | $80.20 | 2019 | |
| Genentech USA, INC. | $68.10 | 2019-2021 | |
| Leo Pharma INC. | $57.05 | 2022-2024 | Adbry |
| Greer Laboratories, INC. | $28.56 | 2020 | |
| Phadia US INC. | $27.61 | 2019 | |
| Organon LLC | $27.56 | 2025 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.46 | 2022 | |
| Incyte Corporation | $26.31 | 2022 | |
| Lilly USA, LLC | $24.13 | 2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $24.01 | 2022 | |
| Kaleo, INC. | $23.88 | 2020 | |
| Galderma Laboratories, L.P. | $20.86 | 2024 | |
| Hikma Pharmaceuticals USA | $17.00 | 2024 | Ryaltris |
| Optinose US, INC. | $15.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.25 | 2020 | |
| Merck Sharp & Dohme LLC | $13.20 | 2023 | |
| Alk-Abello, INC | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sikora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.